Recommendations for RRMS Management
Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, share key takeaways for clinicians treating RRMS.
The Future of RRMS Treatment
Expert neurologists highlight upcoming agents for the treatment of RRMS, focusing on biomarkers.
Challenges in Use of Generic DMTs for Treatment of MS
Experts in neurology provide insight on challenges that arise with the use of generic DMTs in RRMS treatment, such as cost to the patient.
Use of Generic DMTs in Clinical Practice in RRMS
Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, comment on the use of generic DMTs in the treatment of RRMS, highlighting efficacy and safety data as well as level of equivalence to brand name treatments.
Treatment Options for a Patient With RRMS and Psoriasis
Expert neurologists discuss treatment options for a patient with comorbid autoimmune diseases, relapsing/remitting multiple sclerosis, and psoriasis.
Patient Case #2: 36-Year-Old Female With RRMS With Lesions in the Spine and Brain
Ravi Dukkipati, MD, and Gabriel Pardo, MD, FAAN, review the use of rituximab and other disease-modifying therapies in a patient with an established diagnosis of relapsing/remitting multiple sclerosis.
Switching DMTs in Patients With RRMS
Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, discuss a patient case with relapsing/remitting multiple sclerosis progression and share considerations for switching treatment.
Patient Case #1: 37-Year-Old Female With RRMS
Expert neurologists review treatment options for a young female with relapsing remitting multiple sclerosis (RRMS).
Generic DMTs as First-Line Treatment in RRMS
Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, consider reasons to use generic disease-modifying therapies (DMTs) as a first-line therapy in the treatment of relapsing remitting multiple sclerosis (RRMS).
Treatment Selection in RRMS
Experts in neurology highlight factors that lead them to choose certain therapies to treat relapsing remitting multiple sclerosis (RRMS), such as high efficacy in clinical trials.
FDA Approval Process for RRMS Therapies
Gabriel Pardo, MD, FAAN, describes the process that generic RRMS medications have to go through to be approved by the FDA, highlighting the abbreviated new drug application [ANDA] process.
Generic Disease-Modifying Therapies (DMTs) in RRMS
Expert neurologists review availability of generic disease-modifying therapies [DMTs] and the effectiveness of reduced cost to the patient with RRMS
Unmet Needs in the RRMS Treatment Landscape
Ravi Dukkipati, MD, and Gabriel Pardo, MD, FAAN, discuss barriers in accessing treatment for patients with RRMS, as well as a lack of appropriate biomarkers to monitor disease progression.
Advances in the Management of Relapsing-Remitting Multiple Sclerosis (RRMS)
Experts in neurology review recent advances in the treatment landscape of relapse-remitting multiple sclerosis (RRMS) and the ever-present challenge of tailoring treatment to individual patients.
Emerging Therapies and Unmet Needs in MS
Drs Ahmed Zayed and Mark S. Freedman review emerging therapies in the pipeline and unmet needs in the multiple sclerosis treatment landscape, as well as take-home thoughts.
Role of Oral BTKi in MS Management
Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, provides an overview of the different types of Bruton tyrosine kinase inhibitors (BTKi) in management of MS.
Sequencing of Therapies in MS
Experts in neurology highlight the factors they consider when switching treatments for a patient with MS.
Use of Cladribine in MS Treatment
Ahmed Zayed Obeidat MD, PhD, and Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, discuss the use of oral cladribine in the treatment of MS.
Efficacy and Safety of Oral Therapies in MS
Experts in neurology present long-term efficacy and safety data of oral DMTs in the treatment of MS and share their perspective on the real-world significance.
DMT Adherence and Routes of Administration in MS
Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, comments on the different modes of administration of DMTs in MS, focusing on oral DMTs.
Risk of MS Disease Progression and Complementary Diagnostic Tools
Experts in neurology assess the risk of disease progression in a patient with MS and identify various biomarkers and diagnostic tools used to detect this.
Approaching Treatment for MS Management
Drs Ahmed Zayed Obeidat and Mark S. Freedman share considerations for individualized therapy for the management of MS.
Disease-Modifying Therapies (DMTs) in Multiple Sclerosis (MS)
Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, provides an overview of disease-modifying therapies for the treatment of multiple sclerosis.
2 Clarke Drive Cranbury, NJ 08512